Overview

Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This community-based cluster randomized controlled trial aims to evaluate the effectiveness of time-limited, community-wide mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHA-PPQ) and single low-dose primaquine (SLD-PQ) on Plasmodium falciparum transmission compared to standard-of-care seasonal malaria chemoprevention (SMC). The study will be conducted in a moderate-to-low malaria transmission setting of Senegal with optimized malaria control measures (e.g., proactive community case management and piperonyl butoxide pyrethroid long-lasting insecticidal nets (PBO LLINS)).

Phase:

N/A

Details

Lead Sponsor:

University of California, San Francisco

Collaborators:

Centers for Disease Control and Prevention
Population Services International
Programme National de Lutte contre le Paludisme (PNLP), Senegal
Université de Thiès, Senegal
US President's Malaria Initiative

Treatments:

Artenimol
Dihydroartemisinin
Piperaquine
Primaquine